PortfoliosLab logoPortfoliosLab logo
ALPMY vs. DCTH
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ALPMY vs. DCTH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Astellas Pharma Inc (ALPMY) and Delcath Systems, Inc. (DCTH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ALPMY achieves a 1.35% return, which is significantly lower than DCTH's 13.96% return.


ALPMY

1D
0.15%
1M
-5.21%
YTD
1.35%
6M
1.89%
1Y
45.94%
3Y*
-2.47%
5Y*
-4.56%
10Y*
-0.31%

DCTH

1D
-1.54%
1M
4.45%
YTD
13.96%
6M
14.30%
1Y
-16.90%
3Y*
27.37%
5Y*
1.93%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ALPMY vs. DCTH - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
ALPMY
Astellas Pharma Inc
1.35%41.23%-17.10%-21.50%-6.82%5.38%-9.34%35.81%-17.50%
DCTH
Delcath Systems, Inc.
13.96%-16.11%189.42%15.56%-53.55%-56.75%-15.67%-89.16%-90.69%

Correlation

The correlation between ALPMY and DCTH is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.09

Correlation (5Y)
Calculated over the trailing 5-year period

0.10

Correlation (All Time)
Calculated using the full available price history since May 29, 2018

0.11

Fundamentals

Market Cap

ALPMY:

$24.21B

DCTH:

$414.60M

EPS

ALPMY:

¥172.03

DCTH:

$0.01

PE Ratio

ALPMY:

12.65

DCTH:

783.68

PS Ratio

ALPMY:

1.72

DCTH:

6.72

PB Ratio

ALPMY:

2.13

DCTH:

3.68

Total Revenue (TTM)

ALPMY:

¥2.27T

DCTH:

$65.45M

Gross Profit (TTM)

ALPMY:

¥1.69T

DCTH:

$77.75M

EBITDA (TTM)

ALPMY:

¥445.01B

DCTH:

$222.00K

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Astellas Pharma Inc

Delcath Systems, Inc.

Return for Risk

ALPMY vs. DCTH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALPMY
ALPMY Risk / Return Rank: 8080
Overall Rank
ALPMY Sharpe Ratio Rank: 8484
Sharpe Ratio Rank
ALPMY Sortino Ratio Rank: 8181
Sortino Ratio Rank
ALPMY Omega Ratio Rank: 7878
Omega Ratio Rank
ALPMY Calmar Ratio Rank: 7777
Calmar Ratio Rank
ALPMY Martin Ratio Rank: 7979
Martin Ratio Rank

DCTH
DCTH Risk / Return Rank: 2828
Overall Rank
DCTH Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
DCTH Sortino Ratio Rank: 2727
Sortino Ratio Rank
DCTH Omega Ratio Rank: 2727
Omega Ratio Rank
DCTH Calmar Ratio Rank: 2828
Calmar Ratio Rank
DCTH Martin Ratio Rank: 3030
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALPMY vs. DCTH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Astellas Pharma Inc (ALPMY) and Delcath Systems, Inc. (DCTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ALPMYDCTHDifference
Sharpe ratioReturn per unit of total volatility

+1.95

Sortino ratioReturn per unit of downside risk

+2.46

Omega ratioGain probability vs. loss probability

1.28

0.98

+0.30

Calmar ratioReturn relative to maximum drawdown

2.17

-0.41

+2.58

Martin ratioReturn relative to average drawdown

5.85

-0.64

+6.49

ALPMY vs. DCTH - Sharpe Ratio Comparison

The current ALPMY Sharpe Ratio is 1.61, which is higher than the DCTH Sharpe Ratio of -0.34. The chart below compares the historical Sharpe Ratios of ALPMY and DCTH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ALPMY vs. DCTH - Drawdown Comparison

The maximum ALPMY drawdown since its inception was -83.67%, smaller than the maximum DCTH drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for ALPMY and DCTH.


Loading charts...

Drawdown Indicators


ALPMYDCTHDifference

Max Drawdown

Largest peak-to-trough decline

-83.67%

-99.96%

+16.29%

Max Drawdown (1Y)

Largest decline over 1 year

-21.28%

-41.71%

+20.43%

Max Drawdown (3Y)

Largest decline over 3 years

-40.38%

-62.87%

+22.49%

Max Drawdown (5Y)

Largest decline over 5 years

-49.11%

-82.21%

+33.10%

Max Drawdown (10Y)

Largest decline over 10 years

-49.67%

Current Drawdown

Current decline from peak

-75.12%

-99.81%

+24.69%

Average Drawdown

Average peak-to-trough decline

-58.44%

-96.43%

+37.99%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.88%

26.33%

-18.45%

Volatility

ALPMY vs. DCTH - Volatility Comparison

The current volatility for Astellas Pharma Inc (ALPMY) is 9.83%, while Delcath Systems, Inc. (DCTH) has a volatility of 13.30%. This indicates that ALPMY experiences smaller price fluctuations and is considered to be less risky than DCTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ALPMYDCTHDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.83%

13.30%

-3.47%

Volatility (6M)

Calculated over the trailing 6-month period

22.43%

32.57%

-10.14%

Volatility (1Y)

Calculated over the trailing 1-year period

28.73%

49.63%

-20.90%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.42%

73.00%

-47.58%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

25.59%

109.86%

-84.27%

Dividends

ALPMY vs. DCTH - Dividend Comparison

Neither ALPMY nor DCTH has paid dividends to shareholders.


PositionTTM2025202420232022202120202019201820172016
ALPMY
Astellas Pharma Inc
0.00%1.93%2.56%0.00%0.00%0.00%0.00%0.00%0.00%1.20%2.18%
DCTH
Delcath Systems, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

ALPMY vs. DCTH - Financials Comparison

This section allows you to compare key financial metrics between Astellas Pharma Inc and Delcath Systems, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00B200.00B300.00B400.00B500.00B600.00B20222023202420252026
647.49B
0
(ALPMY) Total Revenue
(DCTH) Total Revenue
Please note, different currencies. ALPMY values in JPY, DCTH values in USD

Frequently Asked Questions


ALPMY and DCTH have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

DCTH has higher volatility (13.30%) compared to ALPMY (9.83%). In terms of maximum drawdown, ALPMY dropped -83.67% vs DCTH's -99.96%.

ALPMY currently has the higher Sharpe Ratio (1.61 vs -0.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ALPMY and DCTH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer